Occurrence of Ceftriaxone Resistance in CiprofloxacinResistant Salmonella enterica Serotype Choleraesuis Isolates Causing Recurrent Infection
Sir-The increasing rates of resistance to traditional anti-Salmonella agents (i.e., ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole [TMP-SMX]), extended-spectrum cephalosporins, and fluoroquinolones among Salmonella isolates have made treatment of invasive salmonellosis a clinical dilemma [1] [2] [3] . In Taiwan, the recent emergence of resistance to ciprofloxacin and ceftriaxone among Salmonella species-particularly Salmonella enterica serotype Choleraesuis-has been reported [2, 3] .
A 48-year-old woman had been relatively healthy, without any systemic disease, until she began to experience chills followed by fever starting at the end of August 2002. She was admitted to a hospital once in September 2002 and once in October 2002. Blood cultures performed during the 2 hospitalizations both yielded non-typhoid Salmonella, which was susceptible to ceftriaxone but resistant to ciprofloxacin, as determined with the disk diffusion method. Defeverscence was noted after treatment with cefazolin, and gentamicin was started.
In November 2002, the patient experienced fever again and was admitted to National Taiwan University Hospital (Taipei). Initially, S. Choleraesuis was isolated from 2 sets of blood cultures (isolate A) (table 1), which was resistant to ampicillin, chloramphenicol, TMP-SMX, and ciprofloxacin. The patient was treated with ceftriaxone (1 g q12h). However, hypotension developed on the next day. The antibiotic regimen was changed to imipenem (500 mg q8h), and the patient's fever subsided 2 days later.
Unfortunately, the patient again developed fever associated with abdominal cramping pain and diarrhea on 30 December 2002, at which point she had received imipenem for 13 days and oral ciprofloxacin for 4 days. Blood (isolate B) and stool (isolate C) cultures both yielded the same organism. Intensive diagnostic evaluations, including colonoscopy, abdominal sonography, pelvic CT, and a wholebody gallium scan all yielded negative results. During this episode, imipenem was given for 20 days, followed by oral cefixime (200 mg q12h), and the patient remained afebrile.
In early March 2003, the patient developed fever and bilateral ankle and heel pain. A 3-phase bone scan examination revealed a focal hot spot over the right parietal bone of the skull. Blood culture results were negative. Another course of treatment was given with imipenem for 14 days, and high-dose ciprofloxacin (750 mg q12h) was given for 5 days.
On 30 March 2003, the patient was admitted to the hospital because of a recurrent fever (duration, 4-5 days). Isolates of S. Choleraesuis, which were resistant to chloramphenicol, ampicillin, ceftriaxone, and ciprofloxacin but susceptible to TMP-SMX, were recovered from blood samples (isolate D). Whole-body bone scan demonstrated progression of multiple areas of increased tracer uptake over the skeleton. Chest CT and mammography did not reveal any abnormalities. During this hospitalization, imipenem (500 mg q8h) was administered for 28 days, and the patient was discharged on 2 April 2003.
Another febrile episode occurred on 9 June 2003; it was associated with headache pain over the occipital area, pain over the bilateral calf, and tenderness over both feet. An S. Choleraesuis isolate (isolate E) with different susceptibility patterns (it was resistant to TMP-SMX) was also found in the blood samples. A whole-body gallium survey revealed increased tracer activity in the bilateral para-preverterbal regions at the T12 level. MRI of the spine illustrated multiple bony metastases over the thoracolumbar spine. Fever persisted during imipenem therapy for 12 days. Because drug-associated fever due to imipenem use was suspected, parenteral TMP-SMX was administered, and the fever subsided thereafter. Breakthrough bacteremia due to the same organism (isolate F) occurred on 5 July, and combination therapy with aztreonam, meropenem, and amikacin was given. The patient remained afebrile for 7 days after receiving combination therapy, and she fully recovered after receipt of treatment with the aforementioned agents for 6 weeks.
As determined by the agar dilution method, all of these isolates were found to be resistant to ampicillin, chloramphenicol, ciprofloxacin (MIC, 32-64 mg/ mL), levofloxacin (MIC, 16-32 mg/mL), moxifloxacin (MIC, у32 mg/mL), and garenoxacin (MIC, 132 mg/mL) but to be susceptible to cefepime (MIC, 0.12-1 mg/ mL), imipenem (MIC, 0.25-0.5 mg/mL), ertapenem (MIC, 0.03-0.12 mg/mL), and faropenem (MIC, 0.5-1 mg/mL) (table 1).
All of the 6 ciprofloxacin-resistant isolates had 2-base substitutions in the quinolone resistance-determining region (QRDR) of the gyrA gene at codons 83 (Ser83Phe) and 87 (Asp87Asn) and Ser80Ile in the QRDR of the parC gene. None of these isolates had any mutations in the QRDR of the gyrB or parE gene [3] . Isolates D, E, and F possessed an ∼1.1-kb amplicon, and the sequence of the amplicon was identical to that of bla CMY-2 , which encodes a class C extended-spectrum cephalosporinase [2] . All isolates but isolate D (the TMP-SMX-susceptible isolate) carried class 1 integron, which can be defined by PCR amplification as having a size of 1.8-kb. Sequencing of the 1.8-kb amplicon confirmed that the presence of the integrase (intI1) gene, which encodes resistance to quaternary ammonium compounds and ethidium bromide (qacEDelta) and sulfonamides (sul1), as well as the dhfrXII gene cassette near the 5 converved region (5 CS) [5] . The class 2 integrase (intI2) gene and the cat, cmlA, and floR genes were not detected in any of the 6 isolates. The absence of the class 1 integrase gene (intI1) in isolate D may explain its susceptibility to TMP-SMX [1, 4, 5]. All 6 isolates had similar PFGE profiles with use of 2 restriction enzymes (XbaI and blnI), indicating that they were closely related [3] . This patient had recurrent infection (bacteremia, enterocolitis, and osteomyelitis) during an 11-month period caused by 6 closely related isolates (a single strain) exhibiting variable resistance profiles.
The original ceftriaxone-susceptible and ciprofloxacin-resistant Salmonella isolates could evolve to have resistance to ceftriaxone and could have acquired the bla CMY-2 gene during treatment with multiple antibiotics, including b-lactams. Interestingly, these isolates were similar to the predominant clone of ciprofloxacin-resistant S. Choleraesuis reported previously in Taiwan. This strain was considered to have originated from pigs [3] .
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